Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma

(2021) Lauren Fishbein et al.   PANCREAS

Insights into Mechanisms of Pheochromocytomas and Paragangliomas Driven by Known or New Genetic Drivers

(2021) Shahida K. Flores et al.   Cancers

Metastatic pheochromocytoma and paraganglioma: proceedings of the MEN2019 workshop

(2020) Patricia Dahia et al.   ENDOCRINE-RELATED CANCER

Dataset for the Reporting of Pheochromocytoma and Paraganglioma: Explanations and Recommendations of the Guidelines from the International Collaboration on Cancer Reporting (ICCR)

(2020) Lester D.R. Thompson et al.   HUMAN PATHOLOGY

TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition

(2020) Aurélie Morin et al.   Cell Reports

Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): an ENS@T retrospective study

(2019) Segolene Hescot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine

(2019) Nölting et al.   Cancers

Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or DeconjugatedO-Methylated Catecholamine Metabolites

(2018) Graeme Eisenhofer et al.   CLINICAL CHEMISTRY

TERT structural rearrangements in metastatic pheochromocytomas

(2017) Trisha Dwight et al.   ENDOCRINE-RELATED CANCER

Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma

(2017) Dipti Rao et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years

(2017) Oksana Hamidi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours

(2017) Aidan Flynn et al.   JOURNAL OF PATHOLOGY

Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas

(2016) Franck Patin et al.   CLINICAL BIOCHEMISTRY

CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY

(2016) Hana Turkova et al.   Endocrine Practice

Tumour hypoxia causes DNA hypermethylation by reducing TET activity

(2016) Bernard Thienpont et al.   NATURE

The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study

(2014) Jan Schovanek et al.   BMC CANCER

THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma

(2014) Eric Baudin et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X

(2014) Nan Qin et al.   INTERNATIONAL JOURNAL OF CANCER

Malignant head and neck paragangliomas: Treatment efficacy and prognostic indicators

(2013) Roshan V. Sethi et al.   AMERICAN JOURNAL OF OTOLARYNGOLOGY

SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma

(2013) Eric Letouzé et al.   CANCER CELL

Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma

(2013) Camilo Jimenez et al.   Current Oncology Reports

Malignant pheochromocytoma and paraganglioma: A population level analysis of long-term survival over two decades

(2012) Paolo Goffredo et al.   JOURNAL OF SURGICAL ONCOLOGY

Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status

(2011) Graeme Eisenhofer et al.   EUROPEAN JOURNAL OF CANCER

Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators

(2010) Montserrat Ayala-Ramirez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Malignant head and neck paragangliomas: Is there an optimal treatment strategy?

(2010) Daniel J Moskovic et al.   Head and Neck Optical Diagnostics Society

Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma

(2008) H J L M Timmers et al.   ENDOCRINE-RELATED CANCER